Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results

被引：0
|
作者：
Schuster, S. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Neelapu, S. S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Gause, B. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Muggia, F. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Gockerman, J. P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Sotomayor, E. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Winter, J. N. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Flowers, C. R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Stergiou, A. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Kwak, L. W. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Natl Canc Inst, Bethesda, MD USA
[4] NYU, Med Ctr, New York, NY 10016 USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] Moffit Canc Ctr & Res Inst, Tampa, FL USA
[7] Northwestern Univ, Chicago, IL 60611 USA
[8] Emory Univ, Atlanta, GA 30322 USA
[9] Biovest Int, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Ibritumomab tiuxetan (ZevalinTM) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission:: Interim analysis for safety of a multicenter, phase III clinical trial.
    Radford, JA
    Ketterer, N
    Sebban, C
    Zinzani, PL
    Delaloye, AB
    Rohatiner, A
    Salles, GA
    Kuhlmann, J
    Chlistalla, A
    Hagenbeek, A
    BLOOD, 2003, 102 (11) : 408A - 409A
  • [42] Persistence of lymph node t(14;18) bearing cells in follicular lymphoma patients in clinical complete remission: Proof of principle for maintenance therapy?
    Mayer, J.
    Janikova, A.
    Kren, L.
    Dvorakova, D.
    Kroupova, I.
    Smardova, J.
    Neubauer, J.
    Vasova, I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 102 - 102
  • [43] FC-gamma receptor IIIA (FCGR3A) polymorphism and DFS in follicular lymphoma patients after idiotype vaccination in first remission
    Popa-Mckiver, M. A.
    McCord, A. M.
    Neelapu, S. S.
    Santos, C. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] High dose therapy and autografting for follicular low grade lymphoma in first remission: The Stanford experience.
    Horning, SJ
    Negrin, RS
    Hoppe, RT
    Chao, NJ
    Long, GD
    Rosenberg, SA
    Tierney, K
    Blume, KG
    BLOOD, 1997, 90 (10) : 2641 - 2641
  • [45] Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study
    Niederwieser, Dietger
    Hasenclever, Dirk
    Berdel, Wolfgang E.
    Biemond, Bart J.
    Al-Ali, Haifa
    Chalandon, Yves
    van Gelder, Michel
    Junghanss, Christian
    Gahrton, Goesta
    Haenel, Mathias
    Hehlmann, Ruediger
    Heinicke, Thomas
    Hochhaus, Andreas
    Iacobelli, Simona
    Kooy, Rien van Marwijk
    Kroeger, Nicolaus
    Janssen, Jeroen
    Jentzsch, Madlen
    Breywisch, Frank
    Mohty, Mohamad
    Masouridi-Levrat, Stavroula
    Ossenkoppele, Gert
    Passweg, Jacob
    Poenisch, Wolfram
    Schetelig, Johannes
    Schliemann, Christoph
    Schwind, Sebastian
    Stelljes, Matthias
    Verdonck, Leo F.
    Vucinic, Vladan
    Lowenberg, Bob
    Cornelissen, Jan
    HAEMATOLOGICA, 2025, 110 (01) : 68 - 77
  • [46] Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03
    Taverna, Christian J.
    Martinelli, Giovanni
    Hitz, Felicitas
    Mingrone, Walter
    Pabst, Thomas
    Cevreska, Lidija
    del Giglio, Auro
    Vanazzi, Anna
    Laszlo, Daniele
    Raats, Johann
    Rauch, Daniel
    Vorobiof, A.
    Lohri, Andreas
    Zucca, Emanuele
    Rudolf, Christine Biaggi
    Rondeau, Stephanie
    Rusterholz, Corinne
    Ghielmini, Michele
    BLOOD, 2013, 122 (21)
  • [47] Results published on Phase II clinical trial for dengue vaccine
    O'Hare, Alice
    EXPERT REVIEW OF VACCINES, 2012, 11 (11) : 1287 - 1287
  • [48] Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group
    Popovic, Stevan
    Jovanovic, Darjana
    Mihaljevic, Biljana
    Andjelkovic, Nebojsa
    Marjanovic, Goran
    Marisavljevic, Dragomir
    Vlaisavljevic, Nada
    Popovic, Lazar
    Salma, Svetlana
    Agic, Danijela
    Milosevic, Rajko
    Smiljanic, Mihajlo
    Sretenovic, Snezana
    Djurdjevic, Predrag
    Markovic, Olivera
    Hajder, Jelena
    Govedarovic, Nenad
    JOURNAL OF BUON, 2017, 22 (02): : 487 - 494
  • [49] ABVD versus EVAP as first line therapy for Hodgkin's Lymphoma: Result from a phase III trial
    Sharma, A.
    Bakhshi, S.
    Raina, V.
    Thulkar, S.
    Sharma, D. N.
    Karthik, G.
    Kumar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma
    Roehnisch, Tim
    Then, Cornelia
    Nagel, Wolfgang
    Blumenthal, Christina
    Braciak, Todd
    Donzeau, Mariel
    Boehm, Thomas
    Flaig, Michael
    Bourquin, Carole
    Oduncu, Fuat S.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
12345